The POLARIS Trial

The POLARIS Trial

CONDITION

Cancer

GENDER

Both males and females

AGE GROUP

18 years and above

TRIAL STATUS

Recruiting

POLARIS is a Phase 2 research trial testing a potential new treatment for BRAFV600-mutant positive melanoma that has spread to the brain. The new treatment is called encorafenib (Braftovi) + binimetinib (Mektovi).

The purpose of this research trial is to determine if high‑dose encorafenib and binimetinib versus standard-dose encorafenib and binimetinib are safe and effective in melanoma that has spread to the brain. The standard dose of encorafenib + binimetinib has been approved by the Therapeutic Goods Association (TGA) in Australia for the treatment of patients with unresectable or metastatic melanoma with a BRAFV600E or BRAFV600K mutation but not for the treatment of melanoma that has spread to the brain.

For more information, visit: https://affinityresearch.com.au/polaris/

CONTACT DETAILS

Phone Number: (08) 9242 7640
Email: nursing@affinityresearch.com.au
Location: 42/95 Monash Avenue, Nedlands WA, Australia

CONTACT SITE

Approved By: Bellberry              

Clinical Trial Registry Link: Click Here